AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1516461 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg cefetamet syrup, given orally twice daily for 7 days
Number of subjects: 40
Study 1516461 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/kg cefaclor, given orally twice daily for 7 days
Number of subjects: 40
Study 6237051 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg
Number of subjects: 20
Study 6237051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31223101 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite intervention studies
Number of subjects: 0
Study 31223101 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐post observational studies
Number of subjects: 0
Study 31223101 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 0
Study 29691951 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy sessions, 50 minutes, 5 days/week for 4 weeks
Number of subjects: 3
Study 29691951 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 subjects)
Number of subjects: 3
Study 29691951 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 3
Study 26912469 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by pharmacists to inform patients about adverse effects of medications
Number of subjects: 87
Study 26912469 — intervention group
Group type: COMPARATOR
Intervention: Patients unaware of adverse effects of medications
Number of subjects: 87
Study 24368588 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouth rinsing twice daily and no brushing
Number of subjects: 34
Study 24368588 — intervention group
Group type: COMPARATOR
Intervention: No CHX mouth rinsing and no brushing
Number of subjects: 34
Study 22261136 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with acromioplasty (group I)
Number of subjects: 120
Study 22261136 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair without acromioplasty (group II)
Number of subjects: 120
Study 20498245 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3-g arm (1.5 g twice daily on days 1 to 5, then 1.0 g twice daily)
Number of subjects: 0
Study 20498245 — intervention group
Group type: COMPARATOR
Intervention: MMF 2-g arm (1.0 g twice daily)
Number of subjects: 0
Study 20498245 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3-g arm
Number of subjects: 0
Study 20498245 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA AUC levels <30 mg.h/L
Number of subjects: 0
Study 20498245 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3-g arm and MMF 2-g arm
Number of subjects: 0
Study 17645881 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg/min vitamin C
Number of subjects: 34
Study 17645881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17645881 — intervention group
Group type: COMPARATOR
Intervention: NTG
Number of subjects: 34
Study 15935015 — intervention group
Group type: EXPERIMENTAL
Intervention: Yaktrax Walker (YW)
Number of subjects: 109
Study 15935015 — intervention group
Group type: COMPARATOR
Intervention: Usual winter footwear (UWF)
Number of subjects: 109
Study 12623727 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivid video reenactment of a violent crime
Number of subjects: 2
Study 12623727 — intervention group
Group type: COMPARATOR
Intervention: Crime report newscast
Number of subjects: 2
Study 9819296 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.25 mg twice daily
Number of subjects: 178
Study 9819296 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.50 mg twice daily
Number of subjects: 178
Study 9819296 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 1.0 mg twice daily
Number of subjects: 178
Study 9819296 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (all doses)
Number of subjects: 178
Study 9819296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 8569263 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiang Cheng San (HM group)
Number of subjects: 162
Study 8569263 — intervention group
Group type: COMPARATOR
Intervention: Western drugs (WM group)
Number of subjects: 162
Study 8569263 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiang Cheng San (animal experiments)
Number of subjects: 162
Study 2505630 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil-propofol
Number of subjects: 50
Study 2505630 — intervention group
Group type: COMPARATOR
Intervention: alfentanil-methohexital
Number of subjects: 50
Study 2505630 — intervention group
Group type: COMPARATOR
Intervention: alfentanil-etomidate
Number of subjects: 50
Study 799569 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg
Number of subjects: 15
Study 799569 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 15
Study 29621901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 400 mg/day)
Number of subjects: 276
Study 29621901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 29621901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 276
Study 29621901 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine and Placebo
Number of subjects: 276
Study 28607888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Dissection (CD)
Number of subjects: 103
Study 28607888 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar-Bipolar Dissection (MBD)
Number of subjects: 103
Study 28607888 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation Dissection (CBD)
Number of subjects: 103
Study 28607888 — intervention group
Group type: COMPARATOR
Intervention: All Techniques (CD, MBD, CBD)
Number of subjects: 103
Study 26048144 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted immunotherapeutic approaches
Number of subjects: 0
Study 26048144 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy alone
Number of subjects: 0
Study 23932774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatiguing treadmill running
Number of subjects: 57
Study 23932774 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-injured)
Number of subjects: 57
Study 23932774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle sprain copers
Number of subjects: 57
Study 23932774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle instability group
Number of subjects: 57
Study 21918063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified choco-malt beverage powder (40 g daily for 120 days)
Number of subjects: 300
Study 21918063 — intervention group
Group type: COMPARATOR
Intervention: Matched energy equivalent unfortified placebo (40 g daily for 120 days)
Number of subjects: 300
Study 21918063 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 300
Study 18312044 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 400
Study 18312044 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (100-800 mg/day)
Number of subjects: 400
Study 18312044 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-4 mg/day)
Number of subjects: 400
Study 18312044 — intervention group
Group type: COMPARATOR
Intervention: N/A (control group not specified)
Number of subjects: 400
Study 16176847 — intervention group
Group type: EXPERIMENTAL
Intervention: pTHr.HIVA DNA
Number of subjects: 35
Study 16176847 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Number of subjects: 35
Study 16176847 — intervention group
Group type: EXPERIMENTAL
Intervention: pTHr.HIVA DNA followed by MVA.HIVA (prime-boost)
Number of subjects: 35
Study 14602793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 microg/kg i.v.) in normal women (NW)
Number of subjects: 16
Study 14602793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 microg/kg i.v.) in obese women (OB)
Number of subjects: 16
Study 14602793 — intervention group
Group type: COMPARATOR
Intervention: Ghrelin response comparison between OB and NW
Number of subjects: 16
Study 11324210 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-diameter self-tapping implants (3.25-mm)
Number of subjects: 55
Study 11324210 — intervention group
Group type: COMPARATOR
Intervention: Standard-diameter self-tapping implants (3.75-mm)
Number of subjects: 55
Study 11324210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Narrow-diameter and Standard-diameter)
Number of subjects: 55
Study 9621865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 0
Study 9621865 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study 7838777 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 0
Study 7838777 — intervention group
Group type: COMPARATOR
Intervention: AVID study
Number of subjects: 0
Study 3076661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg/day
Number of subjects: 24
Study 3076661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (2.5-20 mg/day)
Number of subjects: 24
Study 3076661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (twice daily)
Number of subjects: 24
Study 3076661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (active drug)
Number of subjects: 24
Study 1467049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged high intensity exercise training
Number of subjects: 40
Study 1467049 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 321076 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 46
Study 321076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 321076 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (after infection)
Number of subjects: 46
Study 31490292 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior trunk block (15 ml of 0.5% ropivacaine and 5 μg · ml epinephrine)
Number of subjects: 80
Study 31490292 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block (15 ml of 0.5% ropivacaine and 5 μg · ml epinephrine)
Number of subjects: 80
Study 31490292 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 80
Study 31490292 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior trunk block
Number of subjects: 80
Study 28503777 — intervention group
Group type: EXPERIMENTAL
Intervention: 8000 PNU/mL
Number of subjects: 20
Study 28503777 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 PNU/mL
Number of subjects: 20
Study 28503777 — intervention group
Group type: EXPERIMENTAL
Intervention: >8000 PNU/mL
Number of subjects: 20
Study 25182544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide 10 mg
Number of subjects: 79
Study 25182544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide 30 mg
Number of subjects: 79
Study 25182544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide 60 mg
Number of subjects: 79
Study 25182544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 24445367 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF co-administered with lopinavir/ritonavir (LPV/r)
Number of subjects: 741
Study 24445367 — intervention group
Group type: COMPARATOR
Intervention: TDF co-administered with nevirapine (NVP)
Number of subjects: 741
Study 22468897 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 120
Study 22468897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19948614 — intervention group
Group type: EXPERIMENTAL
Intervention: Enemas
Number of subjects: 90
Study 19948614 — intervention group
Group type: COMPARATOR
Intervention: PEG (1.5 g/kg per day for 6 days)
Number of subjects: 90
Study 17515461 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 4783
Study 17515461 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 4783
Study 15062908 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling
Number of subjects: 0
Study 15062908 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial counseling
Number of subjects: 0
Study 15062908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11919478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow detection (PFD)
Number of subjects: 31
Study 11919478 — intervention group
Group type: COMPARATOR
Intervention: Conventional color Doppler (CCD)
Number of subjects: 31
Study 11919478 — intervention group
Group type: COMPARATOR
Intervention: Conventional color Doppler (CCD) in group B
Number of subjects: 31
Study 9679846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 microg once daily for 2 weeks)
Number of subjects: 121
Study 9679846 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray (once daily for 2 weeks)
Number of subjects: 121
Study 7982695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management provided by an assertive community treatment team
Number of subjects: 105
Study 7982695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management provided by individual case managers
Number of subjects: 105
Study 7982695 — intervention group
Group type: COMPARATOR
Intervention: Referral to a community mental health center
Number of subjects: 105
Study 2686995 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 100
Study 2686995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 4237796 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg tetracycline hydrochloride twice daily for three months
Number of subjects: 51
Study 4237796 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 51
Study 31523801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral quadratus lumborum block (40 ml levobupivacaine 0.25%)
Number of subjects: 86
Study 31523801 — intervention group
Group type: COMPARATOR
Intervention: Sham block (control)
Number of subjects: 86
Study 31523801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral quadratus lumborum block
Number of subjects: 86
Study 30943426 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-day dual n-back training following aerobic exercise
Number of subjects: 0
Study 30943426 — intervention group
Group type: COMPARATOR
Intervention: 20-day dual n-back training following reading
Number of subjects: 0
Study 28703374 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Perfusion (MP)
Number of subjects: 141
Study 25270273 — intervention group
Group type: EXPERIMENTAL
Intervention: AR‐13324 ophthalmic solution 0.01%
Number of subjects: 224
Study 25270273 — intervention group
Group type: EXPERIMENTAL
Intervention: AR‐13324 ophthalmic solution 0.02%
Number of subjects: 224
Study 25270273 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 224
Study 23254324 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 34
Study 23254324 — intervention group
Group type: COMPARATOR
Intervention: Wound infusion catheter (WIC)
Number of subjects: 34
Study 21598351 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 383
Study 21598351 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban (high-dose bolus 25 μg/kg plus 12-hr infusion 0.15 μg/kg/min)
Number of subjects: 383
Study 21598351 — intervention group
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Number of subjects: 383
Study 21598351 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalirudin
Number of subjects: 383
Study 21598351 — intervention group
Group type: COMPARATOR
Intervention: tirofiban
Number of subjects: 383
Study 19933933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12152
Study 19933933 — intervention group
Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 12152
Study 16784086 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Mosaic
Number of subjects: 242
Study 16784086 — intervention group
Group type: COMPARATOR
Intervention: CE-SAV
Number of subjects: 242
Study 16784086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 242
Study 16784086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic
Number of subjects: 242
Study 15321995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine IPTp
Number of subjects: 0
Study 15321995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10866899 — intervention group
Group type: EXPERIMENTAL
Intervention: 60%-70% N(2)O in oxygen
Number of subjects: 30
Study 10866899 — intervention group
Group type: COMPARATOR
Intervention: 50% air in oxygen (control group)
Number of subjects: 30
Study 9110076 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating regimen of zidovudine and didanosine
Number of subjects: 38
Study 9110076 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous regimen of zidovudine and didanosine
Number of subjects: 38
Study 9110076 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 38
Study 1530680 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid (ASA)
Number of subjects: 0
Study 1530680 — intervention group
Group type: COMPARATOR
Intervention: Plain acetylsalicylic acid (ASA)
Number of subjects: 0
Study 1530680 — intervention group
Group type: COMPARATOR
Intervention: ASA placebo
Number of subjects: 0
Study 3925488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 0
Study 3925488 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg methylphenidate
Number of subjects: 0
Study 3925488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31801490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐oral carbohydrate load (preOp™)
Number of subjects: 60
Study 31801490 — intervention group
Group type: COMPARATOR
Intervention: Standard pre‐operative fasting
Number of subjects: 60
Study 29338801 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on nutrition, hygiene, and food safety (21-day program)
Number of subjects: 179
Study 27463120 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Internet platform for older people, used for 8 weeks.
Number of subjects: 41
Study 26212891 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal robot-assisted laparoscopic radical prostatectomy
Number of subjects: 120
Study 26212891 — intervention group
Group type: COMPARATOR
Intervention: Extraperitoneal robot-assisted laparoscopic radical prostatectomy
Number of subjects: 120
Study 23743487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 475
Study 23743487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 23743487 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 475
Study 20229377 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-group intervention for universal precautions and teaching skills
Number of subjects: 0
Study 20229377 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control
Number of subjects: 0
Study 18063490 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous combined HRT (LD-HRT) containing 1mg estradiol + 0.5 mg norethisterone acetate
Number of subjects: 1000
Study 18063490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra low dose hormone replacement therapy (Ultra-LD-HRT) containing 0.5 mg of 17beta-estradiol and 0.25 mg of norethisterone acetate
Number of subjects: 1000
Study 18063490 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only 1000 mg of calcium per day
Number of subjects: 1000
Study 16896912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab added to high-dose therapy (HDT)
Number of subjects: 93
Study 16896912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rituximab)
Number of subjects: 93
Study 14504150 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/nitrous oxide
Number of subjects: 50
Study 14504150 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/nitrous oxide
Number of subjects: 50
Study 10536546 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 5 LMA in males
Number of subjects: 40
Study 10536546 — intervention group
Group type: COMPARATOR
Intervention: Size 4 LMA in males
Number of subjects: 40
Study 10536546 — intervention group
Group type: COMPARATOR
Intervention: Size 4 LMA in females
Number of subjects: 40
Study 10536546 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 5 LMA in females
Number of subjects: 40
Study 8603758 — intervention group
Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 0.5 mg x kg⁻¹ x min⁻¹
Number of subjects: 8
Study 8603758 — intervention group
Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 1.0 mg x kg⁻¹ x min⁻¹
Number of subjects: 8
Study 8603758 — intervention group
Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 2.0 mg x kg⁻¹ x min⁻¹
Number of subjects: 8
Study 8603758 — intervention group
Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 4.0 mg x kg⁻¹ x min⁻¹
Number of subjects: 8
Study 8603758 — intervention group
Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 6.0 mg x kg⁻¹ x min⁻¹
Number of subjects: 8
Study 1744374 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 1744374 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 1744374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7024866 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (750 mg/day)
Number of subjects: 0
Study 7024866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1600 mg/day)
Number of subjects: 0
Study 7024866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31512024 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus Ultrasonic Scalpel (UCSD)
Number of subjects: 100
Study 31512024 — intervention group
Group type: COMPARATOR
Intervention: Ligasure Small Jaw Bipolar Device (EBVS)
Number of subjects: 100